|Articles|November 15, 2022
Utilizing Automated High-Throughput SEC Native Mass Spectrometry for mAb Screening
Author(s)Agilent Technologies
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Mastering Phase-Appropriate Characterization for Biologics Approval
2
From Lab to Patient: The Critical Role of Supply Chain & Distribution in the Life Sciences
3
Maximizing Productivity and Scalability with Perfusion Technology
4
Master Analytical Testing for Biologics Products
5
